Last reviewed · How we verify
Immune Modulator
At a glance
| Generic name | Immune Modulator |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer (PHASE1)
- Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma (PHASE2)
- Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma (PHASE1)
- Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ (PHASE1)
- CAN1012 in OED, DCIS, and LCIS. (PHASE1)
- The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting. (PHASE1)
- Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer (PHASE2)
- A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immune Modulator CI brief — competitive landscape report
- Immune Modulator updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI